Clinical Epidemiology Unit, All India Institute of Medical Sciences, New Delhi, India.
Department of Anaesthesiology, Pain Medicine and Critical Care, All India Institute of Medical Sciences, New Delhi, India.
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102324. doi: 10.1016/j.dsx.2021.102324. Epub 2021 Oct 28.
Vitamin C has been used as an anti-oxidant in various diseases including viral illnesses like coronavirus disease (COVID-19).
Meta-analysis of randomized controlled trials (RCT) investigating the role of vitamin C supplementation in COVID-19 was carried out.
Total 6 RCTs including n = 572 patients were included. Vitamin C treatment didn't reduce mortality (RR 0.73, 95% CI 0.42 to 1.27; I = 0%; P = 0.27), ICU length of stay [SMD 0.29, 95% CI -0.05 to 0.63; I = 0%; P = 0.09), hospital length of stay (SMD -0.23, 95% CI -1.04 to 0.58; I = 92%; P = 0.57) and need for invasive mechanical ventilation (Risk Ratio 0.93, 95% CI 0.61 to 1.44; I = 0%; P = 0.76). Further sub-group analysis based on severity of illness (severe vs. non-severe), route of administration (IV vs. oral) and dose (high vs. low) failed to show any observable benefits.
No significant benefit noted with vitamin C administration in COVID-19. Well-designed RCTs with standardized control group needed on this aspect.
维生素 C 已被用作各种疾病的抗氧化剂，包括冠状病毒病 (COVID-19) 等病毒性疾病。
对维生素 C 补充剂在 COVID-19 中的作用进行了随机对照试验 (RCT) 的荟萃分析。
共纳入 6 项 RCT，共纳入 n=572 例患者。维生素 C 治疗并未降低死亡率（RR 0.73，95%CI 0.42 至 1.27；I²=0%；P=0.27）、ICU 住院时间 [SMD 0.29，95%CI -0.05 至 0.63；I²=0%；P=0.09]、住院时间（SMD -0.23，95%CI -1.04 至 0.58；I²=92%；P=0.57）和需要有创机械通气（风险比 0.93，95%CI 0.61 至 1.44；I²=0%；P=0.76）。基于疾病严重程度（严重与非严重）、给药途径（静脉与口服）和剂量（高与低）的进一步亚组分析未能显示出任何可观察到的益处。
COVID-19 患者中给予维生素 C 治疗没有显著益处。需要在这方面进行设计良好的 RCT 并设立标准化的对照组。
